- Home
- CHRS vs PMI Comparison
CHRS vs PMI Comparison
Compare CHRS & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PMI
- Stock Information
- Founded
- CHRS 2010
- PMI 1981
- Country
- CHRS United States
- PMI United States
- Employees
- CHRS N/A
- PMI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PMI
- Sector
- CHRS Health Care
- PMI
- Exchange
- CHRS Nasdaq
- PMI Nasdaq
- Market Cap
- CHRS 186.0M
- PMI 202.7M
- IPO Year
- CHRS 2014
- PMI 2025
- Fundamental
- Price
- CHRS $1.11
- PMI $2.26
- Analyst Decision
- CHRS Strong Buy
- PMI
- Analyst Count
- CHRS 4
- PMI 0
- Target Price
- CHRS $4.51
- PMI N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- PMI 1.9M
- Earning Date
- CHRS 11-06-2025
- PMI 11-14-2025
- Dividend Yield
- CHRS N/A
- PMI N/A
- EPS Growth
- CHRS N/A
- PMI N/A
- EPS
- CHRS 1.34
- PMI N/A
- Revenue
- CHRS $277,728,000.00
- PMI $4,767,000.00
- Revenue This Year
- CHRS N/A
- PMI N/A
- Revenue Next Year
- CHRS $109.48
- PMI N/A
- P/E Ratio
- CHRS $0.82
- PMI N/A
- Revenue Growth
- CHRS 152.07
- PMI 8.81
- 52 Week Low
- CHRS $0.71
- PMI $2.21
- 52 Week High
- CHRS $2.43
- PMI $13.68
- Technical
- Relative Strength Index (RSI)
- CHRS 31.08
- PMI N/A
- Support Level
- CHRS $1.09
- PMI N/A
- Resistance Level
- CHRS $1.25
- PMI N/A
- Average True Range (ATR)
- CHRS 0.13
- PMI 0.00
- MACD
- CHRS -0.04
- PMI 0.00
- Stochastic Oscillator
- CHRS 0.81
- PMI 0.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.